278 related articles for article (PubMed ID: 19640613)
21. Induction of heart valve lesions by small-molecule ALK5 inhibitors.
Anderton MJ; Mellor HR; Bell A; Sadler C; Pass M; Powell S; Steele SJ; Roberts RR; Heier A
Toxicol Pathol; 2011 Oct; 39(6):916-24. PubMed ID: 21859884
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
Jin CH; Krishnaiah M; Sreenu D; Rao KS; Subrahmanyam VB; Park CY; Son JY; Sheen YY; Kim DK
Bioorg Med Chem; 2011 Apr; 19(8):2633-40. PubMed ID: 21435890
[TBL] [Abstract][Full Text] [Related]
23. Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors.
Xie HZ; Li LL; Ren JX; Zou J; Yang L; Wei YQ; Yang SY
Bioorg Med Chem Lett; 2009 Apr; 19(7):1944-9. PubMed ID: 19254842
[TBL] [Abstract][Full Text] [Related]
24. Discovery of potential ZAP-70 kinase inhibitors: pharmacophore design, database screening and docking studies.
Sanam R; Vadivelan S; Tajne S; Narasu L; Rambabu G; Jagarlapudi SA
Eur J Med Chem; 2009 Dec; 44(12):4793-800. PubMed ID: 19674816
[TBL] [Abstract][Full Text] [Related]
25. Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas.
Li HF; Lu T; Zhu T; Jiang YJ; Rao SS; Hu LY; Xin BT; Chen YD
Eur J Med Chem; 2009 Mar; 44(3):1240-9. PubMed ID: 18947905
[TBL] [Abstract][Full Text] [Related]
26. Discovery of a series of 2-(1H-pyrazol-1-yl)pyridines as ALK5 inhibitors with potential utility in the prevention of dermal scarring.
Boys ML; Bian F; Kramer JB; Chio CL; Ren XD; Chen H; Barrett SD; Sexton KE; Iula DM; Filzen GF; Nguyen MN; Angell P; Downs VL; Wang Z; Raheja N; Ellsworth EL; Fakhoury S; Bratton LD; Keller PR; Gowan R; Drummond EM; Maiti SN; Hena MA; Lu L; McConnell P; Knafels JD; Thanabal V; Sun F; Alessi D; McCarthy A; Zhang E; Finzel BC; Patel S; Ciotti SM; Eisma R; Payne NA; Gilbertsen RB; Kostlan CR; Pocalyko DJ; Lala DS
Bioorg Med Chem Lett; 2012 May; 22(10):3392-7. PubMed ID: 22542194
[TBL] [Abstract][Full Text] [Related]
27. Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors.
Schneider G; Geppert T; Hartenfeller M; Reisen F; Klenner A; Reutlinger M; Hähnke V; Hiss JA; Zettl H; Keppner S; Spänkuch B; Schneider P
Future Med Chem; 2011 Mar; 3(4):415-24. PubMed ID: 21452978
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis.
Higashiyama H; Yoshimoto D; Kaise T; Matsubara S; Fujiwara M; Kikkawa H; Asano S; Kinoshita M
Exp Mol Pathol; 2007 Aug; 83(1):39-46. PubMed ID: 17274978
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological evaluation of benzenesulfonamide-substituted 4-(6-alkylpyridin-2-yl)-5-(quinoxalin-6-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
Kim DK; Jung SH; Lee HS; Dewang PM
Eur J Med Chem; 2009 Feb; 44(2):568-76. PubMed ID: 18467006
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and evaluation of indolinones as inhibitors of the transforming growth factor β receptor I (TGFβRI).
Roth GJ; Heckel A; Brandl T; Grauert M; Hoerer S; Kley JT; Schnapp G; Baum P; Mennerich D; Schnapp A; Park JE
J Med Chem; 2010 Oct; 53(20):7287-95. PubMed ID: 20919678
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluation of 1-substituted-3-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Mohan AV; Park CY; Son JY; Sheen YY; Kim DK
Bioorg Med Chem Lett; 2011 Oct; 21(20):6049-53. PubMed ID: 21911290
[TBL] [Abstract][Full Text] [Related]
32. Computational approach to the identification of novel Aurora-A inhibitors.
Morshed MN; Cho YS; Seo SH; Han KC; Yang EG; Pae AN
Bioorg Med Chem; 2011 Jan; 19(2):907-16. PubMed ID: 21194953
[TBL] [Abstract][Full Text] [Related]
33. SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model.
Fu K; Corbley MJ; Sun L; Friedman JE; Shan F; Papadatos JL; Costa D; Lutterodt F; Sweigard H; Bowes S; Choi M; Boriack-Sjodin PA; Arduini RM; Sun D; Newman MN; Zhang X; Mead JN; Chuaqui CE; Cheung HK; Zhang X; Cornebise M; Carter MB; Josiah S; Singh J; Lee WC; Gill A; Ling LE
Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):665-71. PubMed ID: 18202322
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles as inhibitors of transforming growth factor-β type I receptor (ALK5).
Guo C; Zhang C; Li X; Li W; Xu Z; Bao L; Ding Y; Wang L; Li S
Bioorg Med Chem Lett; 2013 Nov; 23(21):5850-4. PubMed ID: 24055046
[TBL] [Abstract][Full Text] [Related]
35. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors.
Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW
Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors.
Sabat M; Wang H; Scorah N; Lawson JD; Atienza J; Kamran R; Hixon MS; Dougan DR
Bioorg Med Chem Lett; 2017 May; 27(9):1955-1961. PubMed ID: 28359790
[TBL] [Abstract][Full Text] [Related]
37. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.
Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW
Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418
[TBL] [Abstract][Full Text] [Related]
38. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors.
Vyas VK; Ghate M; Goel A
J Mol Graph Model; 2013 May; 42():17-25. PubMed ID: 23507201
[TBL] [Abstract][Full Text] [Related]
39. 4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-β type I receptor kinase.
Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Park HJ; Park SJ; Sheen YY; Kim DK
Bioorg Med Chem; 2014 May; 22(9):2724-32. PubMed ID: 24704197
[TBL] [Abstract][Full Text] [Related]
40. Pyrazolone based TGFbetaR1 kinase inhibitors.
Guckian K; Carter MB; Lin EY; Choi M; Sun L; Boriack-Sjodin PA; Chuaqui C; Lane B; Cheung K; Ling L; Lee WC
Bioorg Med Chem Lett; 2010 Jan; 20(1):326-9. PubMed ID: 19914068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
